ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Jiuliang Yan
Matched on OpenAlex author ID A5070347747. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 3
- AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. Co-author DOI 10.3389/fonc.2025.1667445↗
- Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. Co-author DOI 10.1016/j.isci.2022.105723↗
- Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/atm-22-407↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chuntao Wu · 3 shared papers, 2022–2025 · strength 0.55
- Paper AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. DOI 10.3389/fonc.2025.1667445↗
- Paper Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocar… DOI 10.21037/atm-22-407↗
- Paper Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. DOI 10.1016/j.isci.2022.105723↗
- Haitao Gu · 3 shared papers, 2022–2025 · strength 0.55
- Paper AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. DOI 10.3389/fonc.2025.1667445↗
- Paper Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocar… DOI 10.21037/atm-22-407↗
- Paper Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. DOI 10.1016/j.isci.2022.105723↗
- Beiyuan Hu · 2 shared papers, 2022–2023 · strength 0.30
- Jiang Long · 2 shared papers, 2022–2023 · strength 0.30
- Jiang Long · 1 shared paper, 2025 · strength 0.26
- Qiongzhu Dong · 1 shared paper, 2022 · strength 0.15
- Xu Wang · 1 shared paper, 2023 · strength 0.15
- Lei Wang · 1 shared paper, 2023 · strength 0.15
- Qi Zhang · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.